Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients

Recruiting now

Conditions studied: Colorectal Cancer, Breast Cancer

In brief

The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.

Key facts

Study ID

NCT06765252

Run by

Ain Shams University

People needed

80

Starts

2024-04-01

Expected to finish

2025-08-01

Last updated by the study team

2025-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy
• Age > 18 years
• ECOG PS 0-2.

You may not qualify if…

• Patients treated with irinotecan
• Lack of physical integrity of the upper gastrointestinal tract
• Patients with malabsorption syndrome
• Patients having inability to take oral medication
• Patients with poor performance status
• Patients with chronic diarrhea as ulcerative colitis or Crohn's disease

Where it is running

• Department of Clinical Oncology, Faculty of Medicine, Menoufia University — Shibīn al Kawm, Menoufia, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.